Wang Weigang, Eddy Robert, Condeelis John
Experimental Therapeutics, ImClone Systems Incorporated, New York, New York, USA.
Nat Rev Cancer. 2007 Jun;7(6):429-40. doi: 10.1038/nrc2148.
Recent evidence indicates that metastatic capacity is an inherent feature of breast tumours and not a rare, late acquired event. This has led to new models of metastasis. The interpretation of expression-profiling data in the context of these new models has identified the cofilin pathway as a major determinant of metastasis. Recent studies indicate that the overall activity of the cofilin pathway, and not that of any single gene within the pathway, determines the invasive and metastatic phenotype of tumour cells. These results predict that inhibitors directed at the output of the cofilin pathway will have therapeutic benefit in combating metastasis.
近期证据表明,转移能力是乳腺肿瘤的固有特征,而非罕见的、后期获得的事件。这催生了新的转移模型。在这些新模型的背景下对表达谱数据的解读已确定丝切蛋白途径是转移的主要决定因素。近期研究表明,丝切蛋白途径的整体活性而非该途径内任何单个基因的活性决定了肿瘤细胞的侵袭和转移表型。这些结果预示,针对丝切蛋白途径输出端的抑制剂在对抗转移方面将具有治疗益处。